Design of a potent and selective inhibitor of the intermediate- conductance Ca2+-activated K+ channel, IKCa1: A potential immunosuppressant

Heike Wulff, Mark J. Miller, Wolfram Hänsel, Stephan Grissmer, Michael D. Cahalan, K. George Chandy

Research output: Contribution to journalArticle

474 Citations (Scopus)

Abstract

The antimycotic clotrimazole, a potent inhibitor of the intermediate- conductance calcium-activated K+ channel, IKCa1, is in clinical trials for the treatment of sickle cell disease and diarrhea and is effective in ameliorating the symptoms of rheumatoid arthritis. However, inhibition of cytochrome P450 enzymes by clotrimazole limits its therapeutic value. We have used a rational design strategy to develop a clotrimazole analog that selectively inhibits IKCa1 without blocking cytochrome P450 enzymes. A screen of 83 triarylmethanes revealed the pharmacophore for channel block to be different from that required for cytochrome P450 inhibition. The 'lKCa1- pharmacophore' consists of a (2-halogenophenyl)diphenylmethane moiety substituted by an unsubstituted polar π-electron-rich heterocycle (pyrazole or tetrazole) or a -C≡N group, whereas cytochrome P450 inhibition absolutely requires the imidazole ring. A series of pyrazoles, acetonitriles, and tetrazoles were synthesized and found to selectively block IKCa1. TRAM-34 (1- [(2-chlorophenyl)diphenylmethyl]-1H-pyrazole) inhibits the cloned and the native IKCa1 channel in human T lymphocytes with a K(d) of 20-25 nM and is 200- to 1,500-fold selective over other ion channels. Using TRAM-34, we show that blocking IKCa1 in human lymphocytes, in the absence of P450-inhibition, results in suppression of mitogen-stimulated [3H]thymidine incorporation of preactivated lymphocytes with EC50-values of 100 nM-1 μM depending on the donor. Combinations of TRAM-34 and cyclosporin A are more effective in suppressing lymphocyte mitogenesis than either compound alone. Our studies suggest that TRAM-34 and related compounds may hold therapeutic promise as immunosuppressants.

Original languageEnglish (US)
Pages (from-to)8151-8156
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume97
Issue number14
DOIs
StatePublished - Jul 5 2000

Fingerprint

Calcium-Activated Potassium Channels
Immunosuppressive Agents
Cytochrome P-450 Enzyme System
Clotrimazole
Lymphocytes
Acetonitriles
Tetrazoles
Pyrazoles
Sickle Cell Anemia
Ion Channels
Mitogens
Thymidine
Cyclosporine
Diarrhea
Rheumatoid Arthritis
TRAM 34
Clinical Trials
Electrons
T-Lymphocytes
Therapeutics

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Design of a potent and selective inhibitor of the intermediate- conductance Ca2+-activated K+ channel, IKCa1 : A potential immunosuppressant. / Wulff, Heike; Miller, Mark J.; Hänsel, Wolfram; Grissmer, Stephan; Cahalan, Michael D.; Chandy, K. George.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 97, No. 14, 05.07.2000, p. 8151-8156.

Research output: Contribution to journalArticle

@article{be8f9b427a1e4a8f9bbbb4b47722158f,
title = "Design of a potent and selective inhibitor of the intermediate- conductance Ca2+-activated K+ channel, IKCa1: A potential immunosuppressant",
abstract = "The antimycotic clotrimazole, a potent inhibitor of the intermediate- conductance calcium-activated K+ channel, IKCa1, is in clinical trials for the treatment of sickle cell disease and diarrhea and is effective in ameliorating the symptoms of rheumatoid arthritis. However, inhibition of cytochrome P450 enzymes by clotrimazole limits its therapeutic value. We have used a rational design strategy to develop a clotrimazole analog that selectively inhibits IKCa1 without blocking cytochrome P450 enzymes. A screen of 83 triarylmethanes revealed the pharmacophore for channel block to be different from that required for cytochrome P450 inhibition. The 'lKCa1- pharmacophore' consists of a (2-halogenophenyl)diphenylmethane moiety substituted by an unsubstituted polar π-electron-rich heterocycle (pyrazole or tetrazole) or a -C≡N group, whereas cytochrome P450 inhibition absolutely requires the imidazole ring. A series of pyrazoles, acetonitriles, and tetrazoles were synthesized and found to selectively block IKCa1. TRAM-34 (1- [(2-chlorophenyl)diphenylmethyl]-1H-pyrazole) inhibits the cloned and the native IKCa1 channel in human T lymphocytes with a K(d) of 20-25 nM and is 200- to 1,500-fold selective over other ion channels. Using TRAM-34, we show that blocking IKCa1 in human lymphocytes, in the absence of P450-inhibition, results in suppression of mitogen-stimulated [3H]thymidine incorporation of preactivated lymphocytes with EC50-values of 100 nM-1 μM depending on the donor. Combinations of TRAM-34 and cyclosporin A are more effective in suppressing lymphocyte mitogenesis than either compound alone. Our studies suggest that TRAM-34 and related compounds may hold therapeutic promise as immunosuppressants.",
author = "Heike Wulff and Miller, {Mark J.} and Wolfram H{\"a}nsel and Stephan Grissmer and Cahalan, {Michael D.} and Chandy, {K. George}",
year = "2000",
month = "7",
day = "5",
doi = "10.1073/pnas.97.14.8151",
language = "English (US)",
volume = "97",
pages = "8151--8156",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "14",

}

TY - JOUR

T1 - Design of a potent and selective inhibitor of the intermediate- conductance Ca2+-activated K+ channel, IKCa1

T2 - A potential immunosuppressant

AU - Wulff, Heike

AU - Miller, Mark J.

AU - Hänsel, Wolfram

AU - Grissmer, Stephan

AU - Cahalan, Michael D.

AU - Chandy, K. George

PY - 2000/7/5

Y1 - 2000/7/5

N2 - The antimycotic clotrimazole, a potent inhibitor of the intermediate- conductance calcium-activated K+ channel, IKCa1, is in clinical trials for the treatment of sickle cell disease and diarrhea and is effective in ameliorating the symptoms of rheumatoid arthritis. However, inhibition of cytochrome P450 enzymes by clotrimazole limits its therapeutic value. We have used a rational design strategy to develop a clotrimazole analog that selectively inhibits IKCa1 without blocking cytochrome P450 enzymes. A screen of 83 triarylmethanes revealed the pharmacophore for channel block to be different from that required for cytochrome P450 inhibition. The 'lKCa1- pharmacophore' consists of a (2-halogenophenyl)diphenylmethane moiety substituted by an unsubstituted polar π-electron-rich heterocycle (pyrazole or tetrazole) or a -C≡N group, whereas cytochrome P450 inhibition absolutely requires the imidazole ring. A series of pyrazoles, acetonitriles, and tetrazoles were synthesized and found to selectively block IKCa1. TRAM-34 (1- [(2-chlorophenyl)diphenylmethyl]-1H-pyrazole) inhibits the cloned and the native IKCa1 channel in human T lymphocytes with a K(d) of 20-25 nM and is 200- to 1,500-fold selective over other ion channels. Using TRAM-34, we show that blocking IKCa1 in human lymphocytes, in the absence of P450-inhibition, results in suppression of mitogen-stimulated [3H]thymidine incorporation of preactivated lymphocytes with EC50-values of 100 nM-1 μM depending on the donor. Combinations of TRAM-34 and cyclosporin A are more effective in suppressing lymphocyte mitogenesis than either compound alone. Our studies suggest that TRAM-34 and related compounds may hold therapeutic promise as immunosuppressants.

AB - The antimycotic clotrimazole, a potent inhibitor of the intermediate- conductance calcium-activated K+ channel, IKCa1, is in clinical trials for the treatment of sickle cell disease and diarrhea and is effective in ameliorating the symptoms of rheumatoid arthritis. However, inhibition of cytochrome P450 enzymes by clotrimazole limits its therapeutic value. We have used a rational design strategy to develop a clotrimazole analog that selectively inhibits IKCa1 without blocking cytochrome P450 enzymes. A screen of 83 triarylmethanes revealed the pharmacophore for channel block to be different from that required for cytochrome P450 inhibition. The 'lKCa1- pharmacophore' consists of a (2-halogenophenyl)diphenylmethane moiety substituted by an unsubstituted polar π-electron-rich heterocycle (pyrazole or tetrazole) or a -C≡N group, whereas cytochrome P450 inhibition absolutely requires the imidazole ring. A series of pyrazoles, acetonitriles, and tetrazoles were synthesized and found to selectively block IKCa1. TRAM-34 (1- [(2-chlorophenyl)diphenylmethyl]-1H-pyrazole) inhibits the cloned and the native IKCa1 channel in human T lymphocytes with a K(d) of 20-25 nM and is 200- to 1,500-fold selective over other ion channels. Using TRAM-34, we show that blocking IKCa1 in human lymphocytes, in the absence of P450-inhibition, results in suppression of mitogen-stimulated [3H]thymidine incorporation of preactivated lymphocytes with EC50-values of 100 nM-1 μM depending on the donor. Combinations of TRAM-34 and cyclosporin A are more effective in suppressing lymphocyte mitogenesis than either compound alone. Our studies suggest that TRAM-34 and related compounds may hold therapeutic promise as immunosuppressants.

UR - http://www.scopus.com/inward/record.url?scp=0034608869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034608869&partnerID=8YFLogxK

U2 - 10.1073/pnas.97.14.8151

DO - 10.1073/pnas.97.14.8151

M3 - Article

C2 - 10884437

AN - SCOPUS:0034608869

VL - 97

SP - 8151

EP - 8156

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 14

ER -